Reportlinker Adds Bristol-Myers Squibb: Pipeline - Products - Performance - Potential
NEW YORK, Nov. 23, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Bristol-Myers Squibb: Pipeline • Products • Performance • Potential
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Since the merger to form the company in 1989, BMS has consistently been in the top ten research-based pharmaceutical companies in terms of pharmaceutical sales. However, in 2006, BMS reported its third consecutive year of revenue loss, which looked to threaten this position. The company is going through a transitional period, whereby many older products have seen considerable declines in sales due to generic competition whilst newer products begin to establish themselves in the market place. In fiscal 2007, BMS once again returned to revenue growth, but in fiscal 2009 revenues declined 8.7 per cent from the previous year.
This period of transition has been made more difficult due to patent issues surrounding Plavix, the company's top selling product. BMS and its partner sanofi-aventis have been involved in litigation with Apotex since March 2002, following the filing by Apotex of an ANDA for clopidogrel with the FDA. In March 2006, the parties initially agreed a settlement, granting Apotex a royalty-bearing licence to manufacture and sell a generic clopidogrel bisulphate product in the US effective 1st June 2011, three months prior to the patent expiration. However, this agreement failed to receive antitrust clearance from the state attorneys general and consequently the suspended patent litigation was reinstated.
Problems deepened in August 2006, when Apotex decided to launch its 75 mg clopidogrel bisulphate tablets, despite the outstanding patent litigation over the drug. In response, sanofi-aventis and BMS moved for a preliminary injunction ordering Apotex to halt its sales of clopidogrel. On 31st August 2006, it was announced that the US District Court for the Southern District of New York had granted this injunction. However, the Court also ordered sanofi-aventis and BMS to post a bond in the amount of US$400 million to provide security to Apotex should the Court conclude at the end of the patent litigation that the injunction was wrongly imposed.
The patent litigation between Apotex and BMS/sanofi-aventis ended on 15th February 2007 and, in June 2007 it was announced that BMS/sanofi-aventis had been successful and Apotex' generic product will not be released until 2011. The saga surrounding the litigation has already seen Peter Dolan, the company's chief executive for five years, leave the company and has led to several rumours of a merger between BMS and sanofi-aventis. There could be several significant long-term implications to arise from this litigation.
BMS is looking to refresh its product portfolio, adopting a strategy of increased R&D investment despite decreased income. To this end, BMS' research ratio has increased from 12.2 per cent in 2003, to 19.4 per cent in 2009. Higher levels of expenditure have reaped dividends for the company with three new products launched in 2009: Onglyza, Abilify and Sprycel.
There are also several established products in the portfolio which will help drive BMS' pharmaceutical sales in the future. Avapro continues to benefit from co-development and co-marketing with sanofi-aventis and, along with Plavix, is the main focus of their collaboration. BMS is a world leader in virology, with the Sustiva franchise (which now includes Atripla) and Reyataz forecast to be leading competitors in this field for some time. The company is also heavily involved in projects to provide HIV/AIDS treatment on a worldwide scale, most notably in sub-Saharan Africa where there is the highest level of unmet medical need. Within neuroscience, Abilify continues to sell well, whilst in oncology, Erbitux has been launched and is being investigated in a variety of oncology conditions. This versatility should ensure strong sales growth.
More Information...
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
Key product analysis and forecasting
Cardiovascular & Metabolic
Avapro/Avalide (irbesartan)
Plavix/Iscover (clopidrogel)
Virology
Atripla (efavirenz+emtricitabine+ tenofovir disoproxil fumarate)
Baraclude (entecavir)
Reyataz (atazanavir)
Sustiva (efavirenz)
Neuroscience
Abilify (aripiprazole)
Emsam (selegiline transdermal system)
Oncology
Erbitux (cetuximab)
Ixempra (ixabepilone)
Sprycel (dasatinib)
Immunology
Orencia (abatacept)
OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures
To order this report:
: Bristol-Myers Squibb: Pipeline • Products • Performance • Potential
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article